Lineage Cell Therapeutics (LCTX) Treasury Shares (2010 - 2026)

Lineage Cell Therapeutics has reported Treasury Shares for 6 years, with the latest figure at $2.9 million in Q4 2016.

• For the quarter ending Q4 2016, Treasury Shares fell 83.97% year-over-year to $2.9 million; the trailing twelve-month figure through Dec 2016 stood at $2.9 million (down 83.97% YoY), and the FY2016 full-year result was $2.9 million, down 83.97% from the prior year.
• Treasury Shares for Q4 2016 stood at $2.9 million, roughly flat from $2.9 million in the prior quarter.
• The five-year high for Treasury Shares was $939000.0 in Q4 2022, with the low at $248000.0 in Q1 2026.
• Historically, Treasury Shares has averaged $494583.3 across 5 years, with a median of $501000.0 in 2024.
• Annual changes were most pronounced in 2013 — Treasury Shares jumped 413.81% — and 2016, when it plunged 85.47%.
• Lineage Cell Therapeutics' Treasury Shares stood at $8.4 million in 2012, then jumped by 413.81% to $43.0 million in 2013, then plunged by 53.78% to $19.9 million in 2014, then dropped by 9.34% to $18.0 million in 2015, then plunged by 83.97% to $2.9 million in 2016.
• The last three Treasury Shares figures came in at $2.9 million (Q4 2016), $2.9 million (Q3 2016), and $2.9 million (Q2 2016), per Business Quant data.